KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Treasury Shares: 2018-2024

Historic Treasury Shares for Esperion Therapeutics (ESPR) over the last 7 years, with Dec 2024 value amounting to $2.0 million.

  • Esperion Therapeutics' Treasury Shares changed negligibly% to $55.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $55.0 million for FY2024, which is negligibly% changed negligibly from last year.
  • As of FY2024, Esperion Therapeutics' Treasury Shares stood at $55.0 million, which was down 0.00% from $55.0 million recorded in FY2023.
  • Over the past 5 years, Esperion Therapeutics' Treasury Shares peaked at $55.0 million during FY2020, and registered a low of $55.0 million during FY2020.
  • Moreover, its 3-year median value for Treasury Shares was $2.0 million (2024), whereas its average is $2.0 million.
  • Data for Esperion Therapeutics' Treasury Shares shows a peak YoY surged of 710.76% (in 2020) over the last 5 years.
  • Over the past 5 years, Esperion Therapeutics' Treasury Shares (Yearly) stood at $2.0 million in 2020, then remained steady at $2.0 million in 2021, then remained steady at $2.0 million in 2022, then remained steady at $2.0 million in 2023, then remained steady at $2.0 million in 2024.